Back
Innate Pharma SA 10K Form
Buy
56
IPHYF
Innate Pharma SA
Last Price:
2.65
Seasonality Move:
1.38%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive IPHYF News And Ratings
See the #1 stock for the next 7 days that we like better than IPHYF
IPHYF Financial Statistics
Sales & Book Value
| Annual Sales: | $56.19M |
|---|---|
| Cash Flow: | $0 |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.71 |
| Price / Book: | 3.73 |
Profitability
| EPS (TTM): | -0.09670 |
|---|---|
| Net Income (TTM): | $-8.13M |
| Gross Margin: | $61.43M |
| Return on Equity: | -13.68% |
| Return on Assets: | -3.79% |
Innate Pharma SA Earnings Forecast
Key Innate Pharma SA Financial Ratios
- The Gross Profit Margin over the past 16 years for IPHYF is 95.79%.
- The Selling, General & Administrative Expenses for IPHYF have been equal to 22.64% of Gross Profit Margin.
- The Research & Development expenses have been 107.94% of Revenue.
- The Interest Expense is -8.45% of Operating Income.
- The Net Earning history of IPHYF is -14.59% of Total Revenues.
- Per Share Earnings over the last 19 years have been positive in 11 years.
Innate Pharma SA Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | IPHYF |
| Website: | innate-pharma.com |
Debt
| Debt-to-Equity Ratio: | 0.75 |
|---|---|
| Current Ratio: | 3.73 |
| Quick Ratio: | 3.51 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
IPHYF Technical Analysis vs Fundamental Analysis
Buy
56
Innate Pharma SA (IPHYF)
is a Buy
Is Innate Pharma SA a Buy or a Sell?
-
Innate Pharma SA stock is rated a Buy
The current Innate Pharma SA [IPHYF] share price is $2.65. The Score for IPHYF is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.